In another study of 30 patients with advanced melanoma (stages IIIC and IV) with preexisting SAID treated with ipilimumab (anti–CTLA-4) the flare rate was 27%, of which 33% were grade ≥ 3. This evidence concerns the gene CTLA4 and melanoma.